arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BOSTON SCIENTIFIC CORP

BSX
$44.66 ▼ -0.28 (-0.61%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
75 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Neutral
auto_awesome

Analytical Summary

BOSTON SCIENTIFIC CORP shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $65.7B
Dividend Yield
Revenue Growth 7.5%
Op. Margin 21.6%
ROIC 4.0%
FCF / Share $0.87
Trailing P/E 72.0x
Price / Book 2.6x
FCF Yield 2.0%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

75-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.44B
↑ +7.5%
Net Income Profit after all expenses
$905.00M
↑ +13.8%
Operating Margin Operating profit as % of sales
21.6%
↑ +2.3% 72th
FCF / Share Free cash flow per share
$0.87
↑ +655.4%
Long-Term Debt Long-term obligations
$4.81B
— +0.1%

Health Breakdown

Profitability
75
Returns
74
Financial Health
83
Cash Quality
75

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 20 years · 75 quarters